Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial
Two of Sarepta’s DMD Drugs Miss Primary Endpoint in Confirmatory Trial Sarepta Therapeutics reported that two of its Duchenne muscular dystrophy (DMD) drug candidates, AMONDYS 45 (casimer…